Association between gene score and outcome in the Pakistani samples.

<p>Logistic regression was performed for each group. (A) Islamabad study, outcome is MI, and (B) Lahore study, outcome is CHD. Error bars represent 95% confidence intervals.</p

Association between gene score and CHD in NPHSII.

<p>Logistic regression (age adjusted) was performed for each group. Error bars represent 95% confidence intervals.</p

Reclassification of NPHSII participants with the addition of the gene scores to the Framingham conventional risk factor score.

<p>NRI = net reclassification index.</p><p>Reclassification of NPHSII participants with the addition of the gene scores to the Framingham conventional risk factor score.</p

SNPs included in the gene scores.

<p>SNPs marked with an asterisk (*) are included in both the 19 and 13 SNP gene score.</p><p>⁺rs599839 was genotyped instead of rs646776, r² = 0.95 in Europeans</p><p>⁺⁺For rs7412, the protective SNP is included in the gene score</p><p>SNPs included in the gene scores.</p

Baseline Characteristics of NPHSII participants.

<p>All variable are present as the mean plus standard deviation, apart from the Framingham 10 year CHD risk score where the mean and interquartile range are given.</p><p>Baseline Characteristics of NPHSII participants.</p

Characteristics of the Pakistani sample sets.

<p>Categorical variables were compared using a χ² test while continuous variables were compared using Welch’s t-tests.</p><p>* Log transformed data. Geometric mean and approximate SD are given.</p><p>Characteristics of the Pakistani sample sets.</p

Comparison of risk allele frequencies between the control groups from the Pakistani studies and between the combined total of the Pakistani control groups and NPHSII.

<p>Comparisons were performed using tests of proportion. RAF = Risk Allele Frequency, CI = Confidence Interval.</p><p>Comparison of risk allele frequencies between the control groups from the Pakistani studies and between the combined total of the Pakistani control groups and NPHSII.</p

Accepted criteria from Sections 3 and 4 for an acceptable point-of-care test for the detection of urinary pathogens.

<p>Accepted criteria from Sections 3 and 4 for an acceptable point-of-care test for the detection of urinary pathogens.</p

Flow diagram of the Delphi process which developed the criteria required for an acceptable point-of-care test for the detection of urinary pathogens.

<p>Flow diagram of the Delphi process which developed the criteria required for an acceptable point-of-care test for the detection of urinary pathogens.</p

Professional background and geographical location of the participating Delphi panel members.

<p>Professional background and geographical location of the participating Delphi panel members.</p